Last edition
News about "Event-free survival"
Ultomiris Misses Phase 3 Endpoint in Post-Transplant TMA Trial
AstraZeneca shares a phase 3 update on Ultomiris for Haematopoietic Stem Cell Transplant (HSCT)-TMA, showing a trend toward clinical benefit in adults and adolescents as regulatory discussions continue.
Event-free Survival | 28/07/2026 | By News Bureau | 109
Philogen Resubmits EMA Marketing Application for Melanoma Therapy Nidlegy with Updated Phase 3 Data
Philogen has resubmitted its EMA marketing application for investigational melanoma therapy Nidlegy, supported by updated Phase 3 clinical data demonstrating reduced risk of relapse or death and an extended patient follow-up period.
Event-Free Survival | 28/07/2026 | By News Bureau | 101
AstraZeneca's Imfinzi Combination Therapy Improves Survival Outcomes in Phase 3 Bladder Cancer Trial
AstraZeneca’s phase 3 VOLGA trial demonstrated significant survival benefits with Imfinzi and enfortumab vedotin in muscle-invasive bladder cancer patients who are ineligible for cisplatin-based chemotherapy, marking another positive milestone in the company’s immunotherapy programme.
Event-free Survival | 15/05/2026 | By News Bureau | 113
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy